Antiretroviral therapy (ART) has improved survival and changed the disease pattern of HIV infection. However, ART may cause serious side effects, such as metabolic and cardiovascular complications. In addition, immune reconstitution inflammatory syndrome (IRIS) is being increasingly reported in relation to ART. The article presents the consensus of a workshop around 4 key issues: (1) the differences in the response of adults and children to highly active antiretroviral therapy, (2) the mechanism of the new HIV entry inhibitors and its effect on oral markers, (3) the pathogenesis of IRIS and the contradictory findings of the possible oral lesions related with IRIS, (4) and the benefits and barriers associated with using ART in the developing and developed world. The consensus of the workshop was that there is a need for future studies on the oral manifestations of HIV in individuals treated with new ARTs—especially, children. IRIS was considered a promising field for future research; as such, workshop attendees recommended formulating an IRIS–oral lesions case definition and following strict criteria for its diagnosis.
AssefaYKloosH (2008). The public health approach to antiretroviral treatment (ART) service scale-up in Ethiopia: the first two years of free ART, 2005-2007. Ethiop Med J46:401-406.
2.
AutranBCarcelainGLiTSBlancCMathezDTubianaR. (1997). Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science277:112-116.
3.
BarbaroG (2006). Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. Curr HIV Res4:79-85.
4.
BettelliECarrierYGaoWKornTStromTBOukkaM. (2006). Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature441:235-238.
5.
BonhamSMeyaDBBohjanenPRBoulwareDR (2008). Biomarkers of HIV immune reconstitution inflammatory syndrome. Biomark Med2:349-361.
6.
ChenZO’SheaJJ (2008). Th17 cells: a new fate for differentiating helper T cells. Immunol Res41:87-102.
7.
DhasmanaDJDhedaKRavnPWilkinsonRJMeintjesG (2008). Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs68:191-208.
8.
ElstonJWThakerH (2009). Immune reconstitution inflammatory syndrome. Int J STD AIDS20:221-224.
9.
EmmelkampJMRockstrohJK (2008). Maraviroc, risks and benefits: a review of the clinical literature. Expert Opin Drug Saf7:559-569.
10.
FlintSRTappuniALeighJSchmidt-WesthausenAMMacPhailL (2006). Markers of immunodeficiency and mechanisms of HAART therapy on oral lesions. Adv Dent Res19:146-151.
11.
Food and Drug Administration (2010). Antiretroviral drugs used in the treatment of HIV infection. http://www.fda.gov/oashi/aids/virals.html. Accessed November 4, 2010.
Gaitan-CepedaLACeballos-SalobreñaALópez-OrtegaKArzate-MoraNJiménez-SorianoY (2008). Oral lesions and immune reconstitution syndrome in HIV+/AIDS patients receiving highly active antiretroviral therapy: epidemiological evidence. Med Oral Patol Oral Cir Bucal13:E85-E93.
14.
GeboKAJusticeA (2009). HIV infection in the elderly. Curr Infect Dis Rep11:246-254.
15.
GiaquintoCMorelliEFregoneseFRamponOPenazzatoMde RossiA. (2008). Current and future antiretroviral treatment options in paediatric HIV infection. Clin Drug Investig28:375-397.
16.
GiaquintoCRamponOPenazzatoMFregoneseFDe RossiAD’EliaR (2007). Nucleoside and nucleotide reverse transcriptase inhibitors in children. Clin Drug Investig27:509-531.
17.
GlassWGLimJKCholeraRPletnevAGGaoJLMurphyPM (2005). Chemokine receptor CCR5 promoted leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med202:1087-1098.
18.
GreenspanDCancholaAJMacPhailLACheikhBGreenspanJS (2001). Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet357:1411-1412.
19.
HarriesADMakombeSDSchoutenEJBen-SmithAJahnA (2008). Different delivery models for antiretroviral therapy in sub-Saharan Africa in the context of “universal access.”Trans R Soc Trop Med Hyg102:310-311.
JevtovićDJSalemovićDRaninJPesićIZerjavSDjurković-DjakovićO (2005). The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med6:140-143.
22.
KestensLSeddikiNBohjanenPR (2008). Immunopathogenesis of immune reconstitution disease in HIV patients responding to antiretroviral therapy. Curr Opin HIV AIDS3:419-424.
23.
KingMDReznikDAO’DanielsCMLarsenNMOsterholtDBlumbergHM (2002). Human papillomavirus–associated oral warts among human immunodeficiency virus–seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis34:641-648.
24.
LedermanMM (2001). Immune restoration and CD4+ T-cell function with antiretroviral therapies. AIDS15(suppl 2):11-15.
25.
LedermanMMPenn-NicholsonAChoMMosierD (2006). Biology of CCR5 and its role in HIV infection and treatment. JAMA296:815-826.
26.
LeeBAurpibulLSirisanthanaVMangklabruksASirisanthanaTPuthanakitT (2009). Low prevalence of insulin resistance among HIV-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand. HIV Med10:72-78.
27.
MiziaraIDWeberR (2008). Oral lesions as predictors of highly active antiretroviral therapy failure in Brazilian HIV-infected children. J Oral Pathol Med37:99-106.
28.
NoktaM (2008). Oral manifestations associated with HIV infection. Curr HIV/AIDS Rep5:5-12.
29.
NunnASFonsecaEMBastosFIGruskinSSalomonJA (2007). Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. PLoS Med4:e305.
30.
OjikutuBJackCRamjeeG (2007). Provision of antiretroviral therapy in South Africa: unique challenges and remaining obstacles. J Infect Dis196(suppl 3):523-527.
31.
OppermannM (2004). Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal16:1201-1210.
32.
OrtegaKLCeballos-SalobreñaAGaitán-CepedaLAMagalhaesMG (2008). Oral manifestations after immune reconstitution in HIV patients on HAART. Int J STD AIDS19:305-308.
33.
PalellaFJJrDelaneyKMMoormanACLovelessMOFuhrerJSattenGA. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med338:853-860.
34.
PattonLLMcKaigRStraussRRogersDEronJJJr (2000). Changing prevalence of oral manifestations of human immune-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod89:299-304.
35.
Ramírez-AmadorVAEspinosaEGonzález-RamírezIAnaya-SaavedraGOrmsbyCEReyes-TeránG (2009). Identification of oral candidosis, hairy leukoplakia and recurrent oral ulcers as distinct cases of immune reconstitution inflammatory syndrome. Int J STD AIDS20:259-261.
36.
ShelburneSAMontesMHamillRJ (2006). Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother57:167-170.
37.
SterneJAMayMCostagliolaDde WolfFPhillipsANHarrisR.; When to Start Consortium (2009). Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet373:1352-1363.
38.
StringerJSZuluILevyJStringerEMMwangoAChiBH. (2006). Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA296:782-793.
39.
van RossumAMFraaijPLde GrootR (2002). Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis2:93-102.
40.
ViolariACottonMFGibbDMBabikerAGSteynJMahdiSA. (2008). Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med359:2233-2244.
41.
WalenskyRPWoodRWeinsteinMCMartinsonNALosinaEFofanaMO.; CEPAC-International Investigators (2008). Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis197:1324-1332.
42.
WalkerASDoerholtKSharlandMGibbDM;Collaborative HIV Paediatric Study (CHIPS) Steering Committee (2004). Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS18:1915-1924.
43.
WellerICostagliolaDLedergerberBLundgrenJCheneGTouloumiG.: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group (2008). Response to combination antiretroviral therapy: variation by age. AIDS22:1463-1473.
44.
Wools-KaloustianKKimaiyoSMusickBSidleJSiikaANyandikoW. (2009). The impact of the President’s Emergency Plan for AIDS Relief on expansion of HIV care services for adult patients in western Kenya. AIDS23:195-201.
